Literature DB >> 14667749

Screening for hereditary haemochromatosis within families and beyond.

C Anne McCune1, David Ravine, Mark Worwood, Helen A Jackson, H Martyn Evans, David Hutton.   

Abstract

Screening programmes for haemochromatosis that include follow-up identification of relatives are claimed to be cost effective. We assessed uptake of screening by first-degree relatives of two groups of index cases: people homozygous for the C282Y mutation ascertained by genetic screening of blood donors; and patients presenting clinically with haemochro matosis. Only 40 (24%) of 165 relatives of blood donors had been tested. By contrast, testing uptake in 121 relatives of patients diagnosed clinically was more than double that (53%), despite unstructured provision of genetic information. A substantial number of untested relatives had undiagnosed iron overload. Overall efficacy of population screening for haemochromatosis is undermined by these observations.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14667749     DOI: 10.1016/S0140-6736(03)14963-X

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  4 in total

Review 1.  Genetic testing and common disorders in a public health framework: how to assess relevance and possibilities. Background Document to the ESHG recommendations on genetic testing and common disorders.

Authors:  Frauke Becker; Carla G van El; Dolores Ibarreta; Eleni Zika; Stuart Hogarth; Pascal Borry; Anne Cambon-Thomsen; Jean Jacques Cassiman; Gerry Evers-Kiebooms; Shirley Hodgson; A Cécile J W Janssens; Helena Kaariainen; Michael Krawczak; Ulf Kristoffersson; Jan Lubinski; Christine Patch; Victor B Penchaszadeh; Andrew Read; Wolf Rogowski; Jorge Sequeiros; Lisbeth Tranebjaerg; Irene M van Langen; Helen Wallace; Ron Zimmern; Jörg Schmidtke; Martina C Cornel
Journal:  Eur J Hum Genet       Date:  2011-04       Impact factor: 4.246

2.  Iron loading and morbidity among relatives of HFE C282Y homozygotes identified either by population genetic testing or presenting as patients.

Authors:  C A McCune; D Ravine; K Carter; H A Jackson; D Hutton; J Hedderich; M Krawczak; M Worwood
Journal:  Gut       Date:  2005-09-20       Impact factor: 23.059

3.  Prognostic factors and survival in patients with hereditary hemochromatosis and cirrhosis.

Authors:  Melanie D Beaton; Paul C Adams
Journal:  Can J Gastroenterol       Date:  2006-04       Impact factor: 3.522

4.  Primary hemochromatosis presented by porphyria cutanea tarda: a case report.

Authors:  H Jorn Bovenschen; Wynand H P M Vissers
Journal:  Cases J       Date:  2009-06-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.